CAS 857890-39-2

Lenvatinib mesylate

Description:

Lenvatinib mesylate is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, including thyroid cancer and renal cell carcinoma. It works by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, and RET. The substance is characterized by its mesylate salt form, which enhances its solubility and bioavailability. Lenvatinib mesylate is typically administered orally and is known for its pharmacokinetic properties, including a relatively long half-life, allowing for once-daily dosing. Common side effects may include hypertension, fatigue, diarrhea, and decreased appetite. The compound is classified as a targeted therapy, reflecting its mechanism of action that specifically disrupts cancer cell signaling pathways. Its development has been a significant advancement in oncology, providing a therapeutic option for patients with advanced malignancies. As with any medication, careful monitoring and management of side effects are essential during treatment.

Formula: C₂₁H₁₉ClN₄O₄·CH₄O₃S

InChI: InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

InChI key: InChIKey=HWLFIUUAYLEFCT-UHFFFAOYSA-N

SMILES: O(C=1C2=C(C=C(OC)C(C(N)=O)=C2)N=CC1)C3=CC(Cl)=C(NC(NC4CC4)=O)C=C3.S(C)(=O)(=O)O

Synonyms:

• 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Aminophenoxy)-7-Methoxy-6-Quinolinecarboxamide Mesylate
• 4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide mesylate
• 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1)
• 6-Quinolinecarboxamide,4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,monomethanesulfonate
• E 7080 mesylate
• Kisplyx
• Lenvatinib methanesulfonate
• Lenvima
• Lenvatinib mesylate

lenvatinib Mesylate

CAS: 857890-39-2

Formula: C₂₂H₂₃ClN₄O₇S

Purity: 99%

Color and Shape: Solid

Molecular weight: 522.9586

Ref: IN-DA00G3LI

lenvatinib Mesylate

CAS: 857890-39-2

lenvatinib Mesylate

Purity: 99%

Molecular weight: 522.96g/mol

Ref: 54-OR1028251

Lenvatinib Mesylate

CAS: 857890-39-2

Formula: C₂₁H₁₉ClN₄O₄·CH₄O₃S

Molecular weight: 426.86 96.10

Ref: 4Z-L-124035

Lenvatinib mesylate

CAS: 857890-39-2

Lenvatinib mesylate

Purity: ≥98%

Molecular weight: 522.96g/mol

Ref: 54-BUP15748

LENVATINIB MESYLATE

CAS: 857890-39-2

Purity: 95%

Molecular weight: 522.960021972656

Ref: 10-F816149

Lenvatinib mesylate

CAS: 857890-39-2

Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.

Formula: C₂₂H₂₃ClN₄O₇S

Purity: 99.03% - 99.79%

Color and Shape: Solid

Molecular weight: 522.96

Ref: TM-T8541

Lenvatinib Mesylate

Controlled Product

CAS: 857890-39-2

Formula: C₂₁H₁₉ClN₄O₄·CH₄O₃S

Color and Shape: White To Beige

Molecular weight: 522.959

Ref: TR-L215980

Lenvatinib mesylate - Bio-X ™

CAS: 857890-39-2

Lenvatinib is an anti-cancer drug that is a multi-kinase inhibitor for VEGFR1, VEGFR2 and VEGFR. It has been shown to be effective against several cancers such as thyroid cancer and is currently in clinical trials for the treatment of leukaemia and prostate cancer. Furthermore, Lenvatinib also inhibits the activity of other protein kinases, including those involved in inflammatory responses.

Formula: C₂₂H₂₃ClN₄O₇S

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 522.96 g/mol

Ref: 3D-BL166696

Lenvatinib mesylate

CAS: 857890-39-2

VEGFR2 tyrosine kinase inhibitor

Formula: C₂₂H₂₃ClN₄O₇S

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 522.96 g/mol

Ref: 3D-FC71772